Ulisse Biomed SpA (MIL:UBM) EV-to-EBIT : -4.83 (As of Jan. 19, 2025)

Ulisse Biomed SpA EV-to-EBIT Chart

Ulisse Biomed SpA Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EV-to-EBIT	Get a 7-Day Free Trial				-	-3.38	-	-6.96	-

Competitive Comparison of Ulisse Biomed SpA's EV-to-EBIT

For the Biotechnology subindustry, Ulisse Biomed SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ulisse Biomed SpA's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ulisse Biomed SpA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ulisse Biomed SpA's EV-to-EBIT falls into.

Ulisse Biomed SpA EV-to-EBIT Calculation

Ulisse Biomed SpA's EV-to-EBIT for today is calculated as:

Ulisse Biomed SpA's current Enterprise Value is €21.84 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ulisse Biomed SpA's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-4.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ulisse Biomed SpA  (MIL:UBM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ulisse Biomed SpA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Ulisse Biomed SpA's Enterprise Value for the quarter that ended in Jun. 2024 was €21.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ulisse Biomed SpA's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-4.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ulisse Biomed SpA EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ulisse Biomed SpA's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ulisse Biomed SpA Business Description